Cannabis News Box

Despite legalization, the CBD and hemp industries are facing discrimination

Despite legalization, the CBD and hemp industries are facing discrimination

Bethan Rose Jenkins, Cannabis News Writer/Editorial

August 21, 2019

The 2018 U.S. Farm Bill was expected to eliminate the uncertainty that enshrouds the hemp and CBD industries. In spite of it passing with President Donald Trump’s signature in December of last year, a great deal of discrimination still clouds the ambiguous legal CBD market. CBD (cannabidiol) is...

Curaleaf removes CBD health claims from website and social media after FDA warning

Curaleaf removes CBD health claims from website and social media after FDA warning

Bethan Rose Jenkins, Cannabis News Writer/Editorial

August 7, 2019

At the end of last month, leading medical and wellness cannabis operator Curaleaf Holdings Inc. was given a warning by the Food and Drug Administration (FDA) for making false health claims about the CBD-containing products for sale on its website. Curaleaf serves over 150,000 registered medical canna...

CEO of GW Pharma talks about Epidiolex getting FDA approval

CEO of GW Pharma talks about Epidiolex getting FDA approval

Bethan Rose Jenkins, Cannabis News Writer/Editorial

July 2, 2018

On Monday, Justin Gover hit a milestone in his career. He is the CEO of GW Pharmaceuticals – a company that created a cannabis-based medicine called Epidiolex. Not only is Epidiolex being used to treat two forms of epilepsy but also, it is non-psychoactive, what with it containing the cannabis com...

Rescheduling cannabis in the States: Could the decision backfire?

Rescheduling cannabis in the States: Could the decision backfire?

Bethan Rose Jenkins, Cannabis News Writer/Editorial

June 17, 2018

Cannabis is listed as a Schedule I narcotic, but things could be about to change. If the plant is moved to Schedule II, medical patients everywhere will rejoice. But what if the decision to reschedule cannabis in the United States backfires? There's a chance it might. If the Food and Drug Adminis...

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Bethan Rose Jenkins, Cannabis News Writer/Editorial

May 3, 2018

A cannabis-based medication for epilepsy could be the first to gain approval by the Food and Drug Administration (FDA). Created by British company GW Pharmaceuticals, cannabis-based epilepsy treatment Epidiolex will undergo FDA review this June. Things are looking hopeful, with a panel of 13 advisors...

FDA warns companies against claims that cannabis cures diseases

FDA warns companies against claims that cannabis cures diseases

Sara Tiradossi

November 5, 2017

The Food and Drug Administration sent warning letters to four companies on Tuesday, alerting them they cannot market their cannabis products as a treatment for certain diseases. The agency warned the companies about their unsubstantiated claims that their cannabis-derived products, including oils...

FDA commissioner threatens legal action against medical cannabis companies’ medical claims

FDA commissioner threatens legal action against medical cannabis companies’ medical claims

Logan Lowrey-Rasmussen

October 4, 2017

On Tuesday, Food and Drug Administration (FDA) Commissioner Scott Gottlieb said the agency could begin prosecuting cannabis companies who claim unproven health benefits in their products.  The FDA commissioner said entities are developing products and making claims which tout the anti-tumor effec...

Food and Drug Administration